287 related articles for article (PubMed ID: 10915971)
1. [Chirality and drugs].
Testa B; Reist M; Carrupt PA
Ann Pharm Fr; 2000 Jul; 58(4):239-46. PubMed ID: 10915971
[TBL] [Abstract][Full Text] [Related]
2. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
Brocks DR
Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
[TBL] [Abstract][Full Text] [Related]
3. Stereoselectivity in drug metabolism.
Lu H
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):149-58. PubMed ID: 17428147
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologically active compounds in the environment and their chirality.
Kasprzyk-Hordern B
Chem Soc Rev; 2010 Nov; 39(11):4466-503. PubMed ID: 20852776
[TBL] [Abstract][Full Text] [Related]
5. Enantiomeric antidepressant drugs should be considered on individual merit.
Baumann P; Eap CB
Hum Psychopharmacol; 2001 Dec; 16(S2):S85-S92. PubMed ID: 12404713
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
Shah RR
Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
[TBL] [Abstract][Full Text] [Related]
7. Differential properties of enantiomers of commercially available racemates.
Gulati V
J Indian Med Assoc; 2007 Apr; 105(4):173-4, 176. PubMed ID: 17822184
[TBL] [Abstract][Full Text] [Related]
8. Chirality and pharmacokinetics: an area of neglected dimensionality?
Hutt AJ
Drug Metabol Drug Interact; 2007; 22(2-3):79-112. PubMed ID: 17708062
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional view of pharmacology.
Wainer IW
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S4-8. PubMed ID: 1530004
[TBL] [Abstract][Full Text] [Related]
10. Application of thin-layer chromatography in enantiomeric chiral analysis-an overview.
Aboul-Enein HY; El-Awady MI; Heard CM; Nicholls PJ
Biomed Chromatogr; 1999 Dec; 13(8):531-7. PubMed ID: 10611607
[TBL] [Abstract][Full Text] [Related]
11. [Characterization of drug, narcotic and psychotropic drug chirality by statistical methods].
Noszál B; Schiller Z
Acta Pharm Hung; 1999 Apr; 69(2):85-90. PubMed ID: 10389303
[TBL] [Abstract][Full Text] [Related]
12. [The effect of chirality in clinical pharmacology].
Le Corre P; Sado P; Le Verge R
J Pharm Belg; 1991; 46(5):331-47. PubMed ID: 1791526
[TBL] [Abstract][Full Text] [Related]
13. [Chiral switch: towards a better benefit-risk ratio?].
Blin O
Therapie; 2004; 59(6):625-8. PubMed ID: 15789826
[TBL] [Abstract][Full Text] [Related]
14. Chirality and drugs in clinical practice and its ethical aspect.
Banerjee M; Biswas I; Halder S
J Indian Med Assoc; 2009 Jan; 107(1):41-2. PubMed ID: 19588688
[TBL] [Abstract][Full Text] [Related]
15. Effect of chirality on pharmacokinetics and pharmacodynamics.
Crom WR
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S9-14. PubMed ID: 1530005
[TBL] [Abstract][Full Text] [Related]
16. Incoming guidelines on chirality. A challenge for pharmacokinetics in drug development.
Marzo A
Arzneimittelforschung; 1994 Jun; 44(6):791-3. PubMed ID: 8053982
[TBL] [Abstract][Full Text] [Related]
17. [Chiral compounds and their pharmacologic effects].
Slováková A; Hutt AJ
Ceska Slov Farm; 1999 May; 48(3):107-12. PubMed ID: 10422348
[TBL] [Abstract][Full Text] [Related]
18. Bioanalysis of chiral compounds during drug development using a tiered approach.
Jian W; Edom RW; Huang MQ; Weng N
Bioanalysis; 2014 Mar; 6(5):629-39. PubMed ID: 24620805
[TBL] [Abstract][Full Text] [Related]
19. [Stereochemistry--an overlooked problem in medical treatment and research].
Mikkelsen EO
Ugeskr Laeger; 1990 Jul; 152(28):2029-32. PubMed ID: 2195737
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation.
Srinivas NR
Biomed Chromatogr; 2004 May; 18(4):207-33. PubMed ID: 15162384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
